SML1119

LDN-214117

≥98% (HPLC)

• 同義詞: 1-(4-(6-Methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine
• 經驗公式（希爾表示法）: C₂₅H₂₉N₃O₃
• CAS號碼: 1627503-67-6
• 分子量：: 419.52
• 分類程式碼代碼: 51111800
• PubChem物質ID: 329825659
• NACRES: NA.77

屬性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 顏色: white to beige
• 溶解度: DMSO: 10 mg/mL, clear
• 儲存溫度: 2-8°C
• SMILES 字串: CC(C(C1=CC(OC)=C(OC)C(OC)=C1)=C2)=NC=C2C(C=C3)=CC=C3N4CCNCC4
• InChI: 1S/C25H29N3O3/c1-17-22(19-14-23(29-2)25(31-4)24(15-19)30-3)13-20(16-27-17)18-5-7-21(8-6-18)28-11-9-26-10-12-28/h5-8,13-16,26H,9-12H2,1-4H3
• InChI 密鑰: BHUXVRVMMYAXKN-UHFFFAOYSA-N

描述

應用

LDN-214117 has been used in structure-activity relationship (SAR) study to evaluate its potency on selective inhibition of activin receptor-like kinase-2 (ALK2) through the kinome-wide selectivity of (LDN-214117) via enzymatic kinase profiling.[1]

生化／生理作用

LDN-214117 is a selective inhibitor of the bone morphogenetic protein (BMP) type I receptor kinases with high selectivity for BMP versus TGF-β signaling, and low cytotoxicity. LDN-214117 inhibited ALK2 most, with a biochemical IC₅₀ of 24 nM, followed by TNIK, RIPK2, and ABL1. LDN-214117 has a cell-based IC₅₀ for BMP6 of approximately 100 nM and 164-fold selectivity for BMP6 versus TGF-β1. Fibrodysplasia ossificans progressiva (FOP) is a debilitating and progressive heterotopic ossification disease caused by activating mutations of ACVR1 encoding the BMP type I receptor kinase ALK2. LDN-214117 had nearly identical binding affinity for wild-type ALK2 and each of the FOP-causing mutants tested.

LDN-214117 is a selective inhibitor of the bone morphogenetic protein (BMP) type I receptor kinases.

安全資訊

• 象形圖: GHS06
• 訊號詞: Danger
• 危險聲明: H301
• 防範說明: P264 - P270 - P301 + P310 - P405 - P501
• 危險分類: Acute Tox. 3 Oral
• 儲存類別代碼: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable